PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105
NCT ID: NCT03278275
Last Updated: 2022-06-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
116 participants
INTERVENTIONAL
2017-11-01
2021-07-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2
NCT03271281
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
NCT02755675
Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors
NCT04552847
uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer
NCT02960724
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
NCT04510311
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
uPAR PET/CT
One injection of the radioligand 68Ga-NOTA-AE105
One injection of 68Ga-NOTA-AE105
One injection of 68Ga-NORA-AE105
PET/CT
Following injection of 68Ga-NOTA-AE105 the participants will be subjected to whole body PET/CT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
One injection of 68Ga-NOTA-AE105
One injection of 68Ga-NORA-AE105
PET/CT
Following injection of 68Ga-NOTA-AE105 the participants will be subjected to whole body PET/CT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* WHO performance status 0-2
* Must be able to read and understand the patient information in Danish and to give informed consent
Exclusion Criteria
* Breast-feeding
* Weight more than the maximum weight limit for the PET/CT bed of the scanner (140 kg)
* History of allergic reaction attributable to compounds of similar chemical or biologic composition to 68Ga-NODAGA-E\[c(RGDyK)\]2
* In case of broncho-pulmonary NET, the subtype must not be small cell lung cancer (SCLC)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Esben Carlsen
Principle investigator, Medical doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Esben Carlsen, MD
Role: PRINCIPAL_INVESTIGATOR
Rigshospitalet, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-002312-13
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
AK2017-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.